BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/11/2024 8:04:44 AM | Browse: 31 | Download: 31
|
Received |
|
2024-01-12 14:48 |
|
Peer-Review Started |
|
2024-01-12 14:48 |
|
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-01-31 20:43 |
|
Revised |
|
2024-02-08 19:52 |
|
Second Decision |
|
2024-03-19 02:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2024-03-19 11:53 |
|
Articles in Press |
|
2024-03-19 11:53 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-04-02 03:16 |
|
Publish the Manuscript Online |
|
2024-04-11 08:04 |
ISSN |
2307-8960 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Obstetrics & Gynecology |
Manuscript Type |
Case Report |
Article Title |
Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Guang-Di Zhou and Qin Li |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Qin Li, MD, Lecturer, Surgeon, Department of Obstetrics and Gynecology, Shanghai Changhai Hospital, No. 168 Changhai Road, Yangpu District, 200433, Shanghai, China. pekingli@163.com |
Key Words |
Anti-PD-1; Tislelizumab; Ovarian cancer; Relapsed cancer treatment; Immunotherapy; Case report |
Core Tip |
When chemotherapy, poly adenosine diphosphate ribose polymerase inhibitors, and other treatments are ineffective for relapsed refractory ovarian cancer, anti-programmed death 1 immunotherapy may be the last resort. |
Publish Date |
2024-04-11 08:04 |
Citation |
Zhou GD, Li Q. Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report. World J Clin Cases 2024; 12(11): 1967-1973 |
URL |
https://www.wjgnet.com/2307-8960/full/v12/i11/1967.htm |
DOI |
https://dx.doi.org/10.12998/wjcc.v12.i11.1967 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345